You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylprednisolone
Accession NumberDB00959  (APRD00342)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA prednisolone derivative with similar anti-inflammatory action. [PubChem]
Structure
Thumb
Synonyms
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
delta(1)-6alpha-Methylhydrocortisone
Medrate
Medrol
Medrone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Metilprednisolona
Solomet
Urbason
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-medrolInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissuePharmacia & Upjohn Inc1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueRemedy Repack2013-06-112017-06-09Us
Depo-medrolInjection, suspension40 mg/1IntramuscularRemedy Repack2013-04-102017-03-16Us
Depo-medrolInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueA S Medication Solutions1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissuePharmacia & Upjohn Inc1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueRebel Distributors1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissuePharmacia & Upjohn Inc1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueA S Medication Solutions1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueRemedy Repack2014-09-11Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueA S Medication Solutions1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueDispensing Solutions, Inc.1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissuePharmacia & Upjohn Inc1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueA S Medication Solutions1959-05-28Not applicableUs
Depo-medrolInjection, suspension20 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissuePharmacia & Upjohn Inc1959-05-28Not applicableUs
Depo-medrolInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueA S Medication Solutions1959-05-28Not applicableUs
Depo-medrolInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrol (with Preservative) 20 mg/mlSuspension20 mgIntra-articular; Intralesional; Intramuscular; IntrasynovialPfizer1995-12-31Not applicableCanada
Depo-medrol (with Preservative) 40 mg/mlSuspension40 mgIntra-articular; Intralesional; Intramuscular; IntrasynovialPfizer1994-12-31Not applicableCanada
Depo-medrol (with Preservative) 80 mg/mlSuspension80 mgIntra-articular; Intralesional; Intramuscular; IntrasynovialPfizer1994-12-31Not applicableCanada
Depo-medrol 40 mg/mlSuspension40 mgIntra-articular; Intralesional; Intramuscular; IntrasynovialPfizer1960-12-31Not applicableCanada
Depo-medrol 80 mg/mlSuspension80 mgIntra-articular; Intralesional; Intramuscular; IntrasynovialPfizer1969-12-31Not applicableCanada
MedrolTablet4 mg/1OralStat Rx USA1957-10-24Not applicableUs
MedrolTablet16 mg/1OralPharmacia & Upjohn Inc1957-10-24Not applicableUs
MedrolTablet4 mg/1OralA S Medication Solutions1957-10-24Not applicableUs
MedrolTablet4 mg/1OralA S Medication Solutions1957-10-24Not applicableUs
MedrolTablet32 mg/1OralPharmacia & Upjohn Inc1957-10-24Not applicableUs
MedrolTablet2 mg/1OralPharmacia & Upjohn Inc2013-09-20Not applicableUs
MedrolTablet4 mg/1OralRemedy Repack2013-02-19Not applicableUs
MedrolTablet2 mg/1OralPharmacia & Upjohn Inc1957-10-242016-11-18Us
MedrolTablet32 mg/1OralRemedy Repack2011-10-112016-11-29Us
MedrolTablet8 mg/1OralPharmacia & Upjohn Inc1957-10-24Not applicableUs
MedrolTablet4 mg/1OralPharmacia & Upjohn Inc1957-10-24Not applicableUs
Medrol 16 mgTablet16 mgOralPfizer1968-12-31Not applicableCanada
Medrol 4 mgTablet4 mgOralPfizer1960-12-31Not applicableCanada
Medrol Topical 0.25%Cream2.5 mgTopicalPfizer1960-12-312006-08-02Canada
Medroloan II SuikInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueAsclemed Usa, Inc.1959-05-28Not applicableUs
Medroloan SuikInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueAsclemed Usa, Inc.1959-05-28Not applicableUs
MethylprednisoloneTablet8 mg/1OralGreenstone, Llc2013-03-25Not applicableUs
MethylprednisoloneTablet16 mg/1OralGreenstone, Llc2013-03-25Not applicableUs
MethylprednisoloneTablet4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-02-09Not applicableUs
MethylprednisoloneTablet32 mg/1OralGreenstone, Llc2013-03-25Not applicableUs
MethylprednisoloneTablet4 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
MethylprednisoloneTablet4 mg/1OralKeltman Pharmaceuticals Inc.2007-09-14Not applicableUs
MethylprednisoloneTablet4 mg/1OralGreenstone, Llc2011-10-11Not applicableUs
Methylprednisolone Acetate Injectable Suspension USPSuspension40 mgIntra-articular; Intramuscular; Intrasynovial; Soft tissueSandoz Canada Incorporated2003-03-28Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USPSuspension80 mgIntra-articular; Intramuscular; Intrasynovial; Soft tissueSandoz Canada Incorporated2003-04-04Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(80mg/ml With Preservative)Suspension80 mgIntra-articular; Intramuscular; Intrasynovial; Soft tissueSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(40mg/ml With Preservative)Suspension40 mgIntra-articular; Intramuscular; Intrasynovial; Soft tissueSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Sodium Succinate for InjectionPowder, for solution1 gIntramuscular; IntravenousTeva2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for InjectionPowder, for solution5 gIntramuscular; IntravenousTevaNot applicableNot applicableCanada
Methylprednisolone Sodium Succinate for InjectionPowder, for solution40 mgIntramuscular; IntravenousTeva2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for InjectionPowder, for solution125 mgIntramuscular; IntravenousTeva2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for InjectionPowder, for solution500 mgIntramuscular; IntravenousTeva2000-03-01Not applicableCanada
Readysharp Methylprednisolone 80Injection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueTerrain Pharmaceuticals1959-05-28Not applicableUs
Solu-medrolInjection, powder, for solution1 g/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKit; Powder, for solution125 mgIntramuscular; IntravenousPfizer2012-01-18Not applicableCanada
Solu-medrolInjection, powder, for solution40 mg/1IntravenousRemedy Repack2013-04-152017-02-15Us
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-04-01Not applicableUs
Solu-medrolKit; Powder125 mgIntramuscular; IntravenousPfizer1994-12-312015-09-15Canada
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKit; Powder, for solution1 gIntramuscular; IntravenousPfizer1971-12-31Not applicableCanada
Solu-medrolInjection, powder, for solution1 g/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKit; Powder, for solution500 mgIntramuscular; IntravenousPfizer2012-01-18Not applicableCanada
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-04-01Not applicableUs
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolKit; Powder40 mgIntramuscular; IntravenousPfizer1994-12-312015-09-15Canada
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousMesource Pharmaceuticals2014-07-18Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousA S Medication Solutions1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolKit; Powder, for solution500 mgIntramuscular; IntravenousPfizer1970-12-31Not applicableCanada
Solu-medrolInjection, powder, for solution500 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKit; Powder, for solution1 gIntramuscular; IntravenousPfizer2012-02-07Not applicableCanada
Solu-medrolInjection, powder, lyophilized, for solution40 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-01-28Us
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousA S Medication Solutions1959-04-02Not applicableUs
Solu-medrolKit; Powder1 gIntramuscular; IntravenousPfizer1994-12-312015-09-15Canada
Solu-medrolKit; Powder, for solution125 mgIntramuscular; IntravenousPfizer1997-06-102005-08-05Canada
Solu-medrolKit; Powder, for solution40 mgIntramuscular; IntravenousPfizer2012-01-11Not applicableCanada
Solu-medrolInjection, powder, for solution1 g/1IntravenousRemedy Repack2013-02-092017-01-18Us
Solu-medrolInjection, powder, for solution500 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKitPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-02-08Us
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousPharmacia & Upjohn Inc1959-04-02Not applicableUs
Solu-medrolKit; Powder500 mgIntramuscular; IntravenousPfizer1995-12-312015-09-15Canada
Solu-medrolPowder, for solution125 mg/mLIntravenousRemedy Repack2011-12-192016-10-29Us
Solu-medrolKit; Powder, for solution40 mgIntramuscular; IntravenousPfizer1997-06-102005-08-05Canada
Solu-medrolInjection, powder, for solution40 mg/mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/mLIntramuscular; IntravenousA S Medication Solutions1959-04-02Not applicableUs
Solumedrol Inj 125mg Sterile MixovialPowder, for solution125 mgIntramuscular; Intravenous; RectalUpjohn1969-12-311996-09-10Canada
Solumedrol Inj 40mg Sterile MixovialPowder, for solution40 mgIntramuscular; Intravenous; RectalUpjohn1964-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-methapredInjection, powder, lyophilized, for solution40 mg/mLIntramuscular; IntravenousHospira, Inc.2005-12-202016-10-26Us
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2005-12-202016-10-26Us
MethylprednisoloneTablet4 mg/1OralPhysicians Total Care, Inc.2009-10-15Not applicableUs
MethylprednisoloneTablet4 mg/1OralA S Medication Solutions1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralAmerincan Health Packaging2013-11-25Not applicableUs
MethylprednisoloneTablet4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralProficient Rx LP1997-10-31Not applicableUs
MethylprednisoloneTablet16 mg/1OralKaiser Foundations Hospitals2012-09-12Not applicableUs
MethylprednisoloneTablet4 mg/1OralRebel Distributors1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralJubilant Cadista Pharmaceuticals Inc.1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralBreckenridge Pharmaceutical, Inc.2003-11-07Not applicableUs
MethylprednisoloneTablet4 mg/1OralProficient Rx LP2016-05-26Not applicableUs
MethylprednisoloneTablet4 mg/1OralPhysicians Total Care, Inc.1994-11-29Not applicableUs
MethylprednisoloneTablet4 mg/1OralMajor1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralPreferreed Pharmaceuticals Inc.2013-09-03Not applicableUs
MethylprednisoloneTablet4 mg/1OralStat Rx USA1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralRemedy Repack2012-04-18Not applicableUs
MethylprednisoloneTablet4 mg/1OralQualitest1998-12-22Not applicableUs
MethylprednisoloneTablet8 mg/1OralJubilant Cadista Pharmaceuticals Inc.1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1Oralbryant ranch prepack1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralA S Medication Solutions1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralA S Medication Solutions2016-05-26Not applicableUs
MethylprednisoloneTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralDispensing Solutions, Inc.1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralDirectrx2014-01-01Not applicableUs
MethylprednisoloneTablet4 mg/1OralA S Medication Solutions1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralSandoz1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralRemedy Repack2012-03-012016-10-22Us
MethylprednisoloneTablet4 mg/1OralPreferreed Pharmaceuticals Inc.2014-10-08Not applicableUs
MethylprednisoloneTablet4 mg/1OralActavis Pharma Company2016-05-26Not applicableUs
MethylprednisoloneTablet16 mg/1OralJubilant Cadista Pharmaceuticals Inc.1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralUnit Dose Services1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralBlue Point Laboratories2013-08-02Not applicableUs
MethylprednisoloneTablet4 mg/1OralClinical Solutions Wholsesale1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralRemedy Repack2012-09-052017-11-08Us
MethylprednisoloneTablet4 mg/1OralStat Rx USA1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralUnit Dose Services1997-10-31Not applicableUs
MethylprednisoloneTablet4 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralA S Medication Solutions1998-12-22Not applicableUs
MethylprednisoloneTablet4 mg/1OralAidarex Pharmaceuticals LLC1997-10-31Not applicableUs
MethylprednisoloneTablet32 mg/1OralJubilant Cadista Pharmaceuticals Inc.1997-10-31Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueSandoz2009-01-29Not applicableUs
Methylprednisolone AcetateInjection, suspension80 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone AcetateInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueAidarex Pharmaceuticals LLC2006-10-31Not applicableUs
Methylprednisolone AcetateInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueSandoz2009-01-29Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueProficient Rx LP2005-03-08Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissueRebel Distributors2009-03-05Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissueSandoz2009-03-05Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone AcetateInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissueRebel Distributors2009-03-05Not applicableUs
Methylprednisolone AcetateInjection, suspension80 mg/mLIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissueSandoz2009-03-05Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntramuscular; Intrasynovial; Soft tissuePhysicians Total Care, Inc.2012-07-26Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntra-articular; Intralesional; Intramuscular; Soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone AcetateInjection, suspension40 mg/mLIntralesional; Intramuscular; Intrasynovial; Soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/mLIntramuscular; IntravenousAmneal Biosciences2016-11-11Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/1Intramuscular; IntravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousCardinal Health2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/16mLIntramuscular; IntravenousFresenius Kabi2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousAmneal Biosciences2016-11-11Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/1Intramuscular; IntravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/mLIntramuscular; IntravenousFresenius Kabi2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/1Intramuscular; IntravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/mLIntramuscular; IntravenousCardinal Health2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousFresenius Kabi2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution2 g/1Intramuscular; IntravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HybrisilGel10 mg/gTopicalBio Zone Laboratories, Inc.2010-05-05Not applicableUs
International Brands
NameCompany
MedrateNot Available
MedroneNot Available
MeproloneNot Available
SolometNot Available
UrbasonNot Available
Brand mixtures
NameLabellerIngredients
Depo-medrol With LidocainePfizer
Medrol Acne LotionPfizer
Methylprednisolone Sodium Succinate for Injection, USPHospira, Inc.
Neo-medrolPfizer
Neo-medrol Acne LotionPfizer
Physicians Ez Use M-predProficient Rx LP
Readysharp Anesthetics Plus Methylprednisolone 80Terrain Pharmaceuticals
Readysharp-p40Terrain Pharmaceuticals
Readysharp-p80Terrain Pharmaceuticals
Salts
Name/CASStructureProperties
Methylprednisolone acetate
53-36-1
Thumb
  • InChI Key: PLBHSZGDDKCEHR-LFYFAGGJSA-N
  • Monoisotopic Mass: 416.21988875
  • Average Mass: 416.514
DBSALT001157
Methylprednisolone sodium succinate
2375-03-3
Thumb
  • InChI Key: FQISKWAFAHGMGT-SGJOWKDISA-M
  • Monoisotopic Mass: 496.2073123
  • Average Mass: 496.532
DBSALT001158
Categories
UNIIX4W7ZR7023
CAS number83-43-2
WeightAverage: 374.4706
Monoisotopic: 374.20932407
Chemical FormulaC22H30O5
InChI KeyVHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
IUPAC Name
(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])C[[email protected]](C)C2=CC(=O)C=C[C@]12C
Pharmacology
IndicationAdjunctive therapy for short-term administration in rheumatoid arthritis.
Structured Indications
PharmacodynamicsMethylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Mechanism of actionUnbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionOral bioavailability 80-99%
Volume of distributionNot Available
Protein binding78%
Metabolism

Hepatic

Route of eliminationNot Available
Half life1-3 hours
ClearanceNot Available
ToxicityLD50=2000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methylprednisolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Methylprednisolone.Approved
AcetaminophenThe serum concentration of Methylprednisolone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Methylprednisolone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Methylprednisolone.Approved
AfatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Afatinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methylprednisolone.Experimental
AlbendazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinMethylprednisolone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Methylprednisolone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Methylprednisolone can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.Approved
Aluminum hydroxideThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Methylprednisolone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Methylprednisolone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methylprednisolone.Approved
AmiodaroneThe serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine.Approved
Amphotericin BMethylprednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Amsacrine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Methylprednisolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Methylprednisolone.Approved, Investigational
AprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Methylprednisolone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Methylprednisolone can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Methylprednisolone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone.Withdrawn
AzelastineThe serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methylprednisolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone.Approved, Investigational
BazedoxifeneThe serum concentration of Methylprednisolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Methylprednisolone.Investigational
BendroflumethiazideMethylprednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Methylprednisolone.Withdrawn
BenzocaineThe serum concentration of Methylprednisolone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Methylprednisolone.Approved
BepridilThe serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.Approved, Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Methylprednisolone.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Methylprednisolone.Approved, Investigational
BexaroteneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Methylprednisolone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Methylprednisolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Methylprednisolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Methylprednisolone can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Methylprednisolone.Approved
BromocriptineThe serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Methylprednisolone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methylprednisolone.Withdrawn
BumetanideMethylprednisolone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Methylprednisolone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylprednisolone.Approved
CaffeineThe serum concentration of Methylprednisolone can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Methylprednisolone can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Methylprednisolone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Methylprednisolone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Methylprednisolone.Approved, Investigational
CeritinibThe serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideMethylprednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneMethylprednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Methylprednisolone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Methylprednisolone can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methylprednisolone.Experimental
CilazaprilThe serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Methylprednisolone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Methylprednisolone can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Methylprednisolone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Methylprednisolone.Approved
ClotrimazoleThe metabolism of Methylprednisolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Methylprednisolone can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Methylprednisolone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Methylprednisolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Methylprednisolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Methylprednisolone.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.Approved, Investigational
CyclosporineThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Methylprednisolone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Methylprednisolone.Investigational
DabrafenibThe serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Methylprednisolone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Methylprednisolone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Methylprednisolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methylprednisolone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Methylprednisolone.Investigational
DesipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Methylprednisolone.Approved
DesloratadineThe serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Methylprednisolone can be increased when it is combined with Dextromethorphan.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Methylprednisolone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved
DihydroergotamineThe metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneMethylprednisolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Methylprednisolone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Methylprednisolone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Methylprednisolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Methylprednisolone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Methylprednisolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Methylprednisolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methylprednisolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Methylprednisolone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Methylprednisolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Methylprednisolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Methylprednisolone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Methylprednisolone can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.Approved
EnalaprilThe serum concentration of Methylprednisolone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Methylprednisolone.Approved
ErgonovineThe serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Methylprednisolone can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Methylprednisolone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Methylprednisolone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Methylprednisolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Methylprednisolone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Methylprednisolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Methylprednisolone can be increased when it is combined with Estrone.Approved
Etacrynic acidMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Methylprednisolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Methylprednisolone.Approved
EtoposideThe serum concentration of Methylprednisolone can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone.Approved, Investigational
EtravirineThe serum concentration of Methylprednisolone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Methylprednisolone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Methylprednisolone.Investigational
FelodipineThe serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Methylprednisolone.Approved
FentanylThe serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fenthion.Vet Approved
FexofenadineThe serum concentration of Methylprednisolone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Methylprednisolone can be increased when it is combined with Fidaxomicin.Approved
FingolimodMethylprednisolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Methylprednisolone.Approved, Withdrawn
FluconazoleThe metabolism of Methylprednisolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Methylprednisolone.Vet Approved
FluoxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneMethylprednisolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Methylprednisolone.Approved, Investigational
FluvoxamineThe metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Methylprednisolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideMethylprednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Methylprednisolone can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Methylprednisolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Methylprednisolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methylprednisolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.Approved
GlyburideThe serum concentration of Methylprednisolone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Methylprednisolone can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Methylprednisolone.Approved
Gramicidin DThe serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methylprednisolone.Investigational
HaloperidolThe serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol.Approved
HexestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Methylprednisolone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Methylprednisolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.Approved, Investigational
HydrochlorothiazideMethylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Methylprednisolone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideMethylprednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Methylprednisolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Methylprednisolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Methylprednisolone.Approved
IdelalisibThe serum concentration of Methylprednisolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Methylprednisolone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Methylprednisolone.Approved
IndapamideMethylprednisolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Methylprednisolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Methylprednisolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Methylprednisolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methylprednisolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methylprednisolone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone.Approved
IsavuconazoniumThe metabolism of Methylprednisolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Methylprednisolone.Withdrawn
IsradipineThe metabolism of Methylprednisolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Methylprednisolone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Methylprednisolone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Methylprednisolone.Experimental
KetamineThe serum concentration of Methylprednisolone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone.Approved
LansoprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Methylprednisolone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Methylprednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone.Approved
LiothyronineThe serum concentration of Methylprednisolone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Methylprednisolone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methylprednisolone.Approved
LisinoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Methylprednisolone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Methylprednisolone can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Methylprednisolone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone.Approved
LosartanThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Methylprednisolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Methylprednisolone.Approved
LuliconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methylprednisolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Methylprednisolone.Approved, Investigational
MagaldrateThe bioavailability of Methylprednisolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Methylprednisolone.Approved
Magnesium TrisilicateThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Methylprednisolone.Approved
MebendazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Methylprednisolone.Approved
MefloquineThe serum concentration of Methylprednisolone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Methylprednisolone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone.Approved
MestranolThe serum concentration of Methylprednisolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.Approved
MethadoneThe serum concentration of Methylprednisolone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideMethylprednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneMethylprednisolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneMethylprednisolone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Methylprednisolone can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Methylprednisolone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methylprednisolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methylprednisolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
MitomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Methylprednisolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Methylprednisolone.Investigational
ModafinilThe serum concentration of Methylprednisolone can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Methylprednisolone can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone.Investigational
NafcillinThe serum concentration of Methylprednisolone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Methylprednisolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Methylprednisolone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Methylprednisolone.Approved, Vet Approved
NaringeninThe serum concentration of Methylprednisolone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Methylprednisolone.Investigational
NefazodoneThe serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Methylprednisolone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Methylprednisolone.Approved
NetupitantThe serum concentration of Methylprednisolone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Methylprednisolone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Methylprednisolone.Approved
NilotinibThe metabolism of Methylprednisolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methylprednisolone.Approved, Withdrawn
NisoldipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methylprednisolone.Investigational
NorethisteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Methylprednisolone can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Methylprednisolone.Experimental
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methylprednisolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone.Approved
OmeprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Methylprednisolone.Vet Approved
OsimertinibThe serum concentration of Methylprednisolone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Methylprednisolone.Approved
OxandroloneMethylprednisolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone.Approved
OxymetholoneMethylprednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Methylprednisolone.Withdrawn
P-NitrophenolThe serum concentration of Methylprednisolone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylprednisolone.Approved, Vet Approved
PalbociclibThe serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Methylprednisolone.Approved
ParoxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methylprednisolone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Methylprednisolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Methylprednisolone.Approved, Vet Approved
PhenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.Approved, Investigational
PimozideThe serum concentration of Methylprednisolone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methylprednisolone.Approved, Investigational
PiretanideMethylprednisolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Methylprednisolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Methylprednisolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideMethylprednisolone may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
PravastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Methylprednisolone can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Methylprednisolone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Methylprednisolone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Methylprednisolone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Methylprednisolone.Approved
PropafenoneThe serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Methylprednisolone can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Methylprednisolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Methylprednisolone can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneMethylprednisolone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Methylprednisolone.Approved
RanitidineThe serum concentration of Methylprednisolone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Methylprednisolone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Methylprednisolone.Withdrawn
ReboxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Methylprednisolone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
ReserpineThe serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone.Experimental, Investigational
RifabutinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Methylprednisolone can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with CDX-110.Investigational
RitonavirThe serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Methylprednisolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Methylprednisolone.Approved
RolapitantThe serum concentration of Methylprednisolone can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methylprednisolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Methylprednisolone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Methylprednisolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Methylprednisolone.Approved
SaquinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone.Approved
ScopolamineThe serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Methylprednisolone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Methylprednisolone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Methylprednisolone.Approved, Investigational
SertralineThe serum concentration of Methylprednisolone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Methylprednisolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Methylprednisolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.Approved
SirolimusThe serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methylprednisolone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Methylprednisolone.Approved
SorafenibThe serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sparfloxacin.Approved
SpironolactoneThe serum concentration of Methylprednisolone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Methylprednisolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Methylprednisolone.Investigational
St. John's WortThe serum concentration of Methylprednisolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololMethylprednisolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Methylprednisolone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Methylprednisolone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Methylprednisolone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methylprednisolone.Approved
SulfinpyrazoneThe serum concentration of Methylprednisolone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Methylprednisolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Methylprednisolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone.Approved, Investigational
SumatriptanThe serum concentration of Methylprednisolone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone.Approved, Investigational
TacrolimusThe serum concentration of Methylprednisolone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Methylprednisolone can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Methylprednisolone.Approved
TelithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Methylprednisolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Methylprednisolone.Vet Approved
TerazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Methylprednisolone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Methylprednisolone.Approved
TesmilifeneThe serum concentration of Methylprednisolone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Methylprednisolone can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Methylprednisolone is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Methylprednisolone.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Methylprednisolone.Approved
TiboloneThe serum concentration of Methylprednisolone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Methylprednisolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Methylprednisolone.Investigational
TocilizumabThe serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibMethylprednisolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Methylprednisolone.Approved
TolvaptanThe serum concentration of Methylprednisolone can be increased when it is combined with Tolvaptan.Approved
TorasemideMethylprednisolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Methylprednisolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Methylprednisolone.Approved, Investigational
TrazodoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Methylprednisolone.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methylprednisolone.Withdrawn
TroleandomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Methylprednisolone.Investigational, Withdrawn
VenlafaxineThe metabolism of Methylprednisolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Methylprednisolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone.Approved, Investigational
VinblastineThe serum concentration of Methylprednisolone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methylprednisolone.Approved, Investigational
VoriconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinMethylprednisolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Methylprednisolone.Approved
ZeranolThe serum concentration of Methylprednisolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Methylprednisolone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Methylprednisolone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Methylprednisolone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, “Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use.” U.S. Patent US4587236, issued March, 1973.

US4587236
General References
  1. Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225 ]
External Links
ATC CodesS01CA08D07CA02H02AB04D10AA02D07AA01H02BX01
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (72.6 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceInnate Immunity1
0RecruitingTreatmentCHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT1
0RecruitingTreatmentFriedreich's Ataxia1
0TerminatedTreatmentComplication of Anesthesia During Pregnancy, Unspecified / Fevers / Labour Pain1
1Active Not RecruitingSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentLymphoma NOS1
1Active Not RecruitingTreatmentMultiple Sclerosis (MS)1
1Active Not RecruitingTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1CompletedBasic ScienceBiological Availability1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition1
1CompletedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentMultiple Sclerosis (MS)1
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentOsteoarthritis,Knee1
1RecruitingBasic ScienceNormal Physiology1
1RecruitingTreatmentCongenital Hypoplastic Anemia1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
1RecruitingTreatmentNeuromyelitis Optica1
1RecruitingTreatmentOcular GVHD1
1RecruitingTreatmentProgressive Multiple Sclerosis1
1TerminatedNot AvailableHealthy Volunteers / Multiple Sclerosis (MS)1
1WithdrawnBasic ScienceTherapeutic Equivalency3
1, 2CompletedPreventionOvarian Hyperstimulation Syndrome1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentCongenital Hypoplastic Anemia1
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentSpinal Cord Injuries (SCI)1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Not Yet RecruitingPreventionNoise-Induced Hearing Loss1
1, 2RecruitingNot AvailableAtherosclerosis1
1, 2RecruitingPreventionCognitive Retention Disorder / Postoperative Complications1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia1
1, 2RecruitingTreatmentDrug-Induced Liver Injury, Chronic1
1, 2RecruitingTreatmentInhospital Cardiac Arrest1
1, 2TerminatedTreatmentLeukemias1
1, 2TerminatedTreatmentLeukemias / Myelomas / Myeloproliferative Diseases1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Juvenile Myelomonocytic Leukemia / Previously Treated Childhood Rhabdomyosarcoma / Previously Treated Myelodysplastic Syndromes / Pulmonary Complications / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Neuroblastoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAnkylosing Spondylitis (AS)1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Active Not RecruitingTreatmentEarly and Severe Systemic Sclerosis1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentLymphoma NOS2
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentMultiple Sclerosis, Relapsing-Remitting1
2Active Not RecruitingTreatmentTransplantation, Kidney2
2CompletedDiagnosticLymphoma NOS1
2CompletedSupportive CareCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Neuroblastomas / Testicular germ cell tumour2
2CompletedSupportive CareCancers1
2CompletedSupportive CareLymphoma NOS / Neutropenias1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Postoperative Complications1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdverse Effect of Radiation Therapy / Brain Necrosis / Nasopharyngeal Carcinoma1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAplastic Anaemia (AA)1
2CompletedTreatmentAplastic Anaemia (AA) / Myelodysplastic Syndrome1
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCarcinomatosis / Intestinal Obstruction / Peritoneal Neoplasms1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChronic B-Lymphocytic Leukemia1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia1
2CompletedTreatmentConnective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity1
2CompletedTreatmentGiant Cell Myocarditis / Myocarditis1
2CompletedTreatmentGraft Rejection1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentHantavirus Infections1
2CompletedTreatmentHormone Resistant Prostate Cancer / Prostate Cancer Metastatic1
2CompletedTreatmentKidney Failure,Chronic / Transplantation, Kidney1
2CompletedTreatmentLeukemias3
2CompletedTreatmentLeukemias / Lymphoma NOS1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLupus Erythematosus, Systemic1
2CompletedTreatmentLymphoma NOS3
2CompletedTreatmentMicroscopic Polyangiitis / Renal Limited Vasculitis / Wegener Granulomatosis (WG)1
2CompletedTreatmentNephritis, Lupus1
2CompletedTreatmentProgressive Multiple Sclerosis1
2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentRheumatoid Arthritis2
2Not Yet RecruitingTreatmentAcute-graft-versus-host Disease1
2Not Yet RecruitingTreatmentLeukemias1
2Not Yet RecruitingTreatmentSuspected Appendicitis1
2RecruitingPreventionHyperalgesia / Knee Joint Osteoarthrosis / Severe Movement Related Pain1
2RecruitingTreatmentAdrenoleukodystrophy / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Gangliosidosis / Glycoprotein Metabolic Disorders / Hunter Syndrome / Hurler's Syndrome / I-Cell Disease / Leukodystrophy, Globoid Cell / Maroteaux Lamy Syndrome / Metachromatic Leukodystrophy / Mucopolysaccharidosis II / Mucopolysaccharidosis VI / Mucopolysaccharidosis VII / Niemann Pick B / Niemann Pick C Subtype 2 / Osteopetrosis / Peroxisomal Disorders / Sly Syndrome / Sphingolipidosis / Type 1 Mucopolysaccharidosis1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAplastic Anaemia (AA) / Hypoplastic Myelodysplastic Syndrome1
2RecruitingTreatmentChildhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2RecruitingTreatmentCongenital Hypoplastic Anemia1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentElective Cardiac Surgery1
2RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentHematological Malignancy1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis1
2RecruitingTreatmentIgA Glomerulonephritis / Necrosis / Peripapillary Crescent / Steroid Nephropathy1
2RecruitingTreatmentLeukemias5
2RecruitingTreatmentLung Cancers / Melanoma / Renal Cell Carcinoma (RCC)1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentNephritis, Lupus2
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentPelvic Girdle Pain1
2RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2RecruitingTreatmentSpondylarthropathy1
2RecruitingTreatmentTransplant, Kidney1
2SuspendedNot AvailableAcute Exacerbation of Remitting Relapsing Multiple Sclerosis / Clinically Isolated Syndrome (CIS)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentGraves Ophthalmopathy1
2TerminatedTreatmentInsufficiency; Hepatic, Postoperative / Ischemic Reperfusion Injury / Liver Tumour1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentPrimary Renal Allograft Candidate / Transplantation, Kidney1
2TerminatedTreatmentPrimary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation1
2TerminatedTreatmentRenal Transplant1
2TerminatedTreatmentRheumatoid Arthritis3
2TerminatedTreatmentTransplantation, Kidney / Transplantation, Renal1
2WithdrawnTreatmentAcute Graft Versus Host Disease / Intestinal Graft Versus Host Disease1
2WithdrawnTreatmentAdult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS-Related1
2WithdrawnTreatmentChronic Graft Versus Host Disease1
2WithdrawnTreatmentMultiple Sclerosis (MS)1
2WithdrawnTreatmentMyelomas1
2WithdrawnTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3Active Not RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedNot AvailableOsteoarthrosis2
2, 3CompletedTreatmentAutoimmune Diseases / Scleroderma, Systemic / Sclerosis1
2, 3CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
2, 3CompletedTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLumbosacral Radiculopathy1
2, 3CompletedTreatmentMeniere's Disease1
2, 3CompletedTreatmentMicroscopic Polyangiitis / Vasculitis / Wegener Granulomatosis (WG)1
2, 3CompletedTreatmentOphthalmopathy, Thyroid-Associated1
2, 3CompletedTreatmentSinusitis1
2, 3Not Yet RecruitingTreatmentAcute Lung Injury (ALI) / ARDS, Human1
2, 3Not Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Gout1
2, 3Not Yet RecruitingTreatmentThyroid Eye Disease1
2, 3RecruitingPreventionComplications1
2, 3RecruitingTreatmentAcute Alcoholic Hepatitis1
2, 3RecruitingTreatmentLeukemias1
2, 3TerminatedTreatmentLupus Erythematosus, Systemic1
2, 3TerminatedTreatmentMultiple Sclerosis (MS)1
3Active Not RecruitingSupportive CareGraft Versus Host Disease (GVHD)1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentCarcinoma of the Prostate1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentLeukemias / Lymphoma NOS1
3Active Not RecruitingTreatmentLymphoma NOS1
3Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3Active Not RecruitingTreatmentMultiple Sclerosis (MS) / Optic Neuritis1
3Active Not RecruitingTreatmentMultiple Sclerosis, Primary Progressive1
3Active Not RecruitingTreatmentTransplantation, Kidney1
3Active Not RecruitingTreatmentVestibular Neuritis1
3CompletedNot AvailableOsteoarthrosis1
3CompletedPreventionFacial Palsy1
3CompletedPreventionKidney Diseases1
3CompletedPreventionPost-Extubation Laryngeal Edema1
3CompletedPreventionTransplantation, Kidney1
3CompletedSupportive CareCancers / Pain1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)1
3CompletedSupportive CareGraft Versus Host Disease (GVHD) / Recurrent Adult Acute Lymphoblastic Leukemia1
3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentBronchopulmonary Dysplasia1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentChronic Kidney Disease (CKD) / IgA Nephropathy1
3CompletedTreatmentChronic Lung Diseases / Respiratory Distress Syndrome, Adult1
3CompletedTreatmentHeart Diseases / Heart Transplantation1
3CompletedTreatmentHemangiomas1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLymphoma NOS3
3CompletedTreatmentMultiple Sclerosis, Chronic Progressive1
3CompletedTreatmentNephritis, Lupus1
3CompletedTreatmentRheumatoid Arthritis4
3CompletedTreatmentSpinal Cord Injuries (SCI)1
3CompletedTreatmentSudden Deafness1
3CompletedTreatmentTransplantation, Kidney2
3Not Yet RecruitingTreatmentChronic Subdural Hematomas1
3Not Yet RecruitingTreatmentDexamethasone-induced Hiccup in Chemotherapy1
3Not Yet RecruitingTreatmentImmunocompromised Patients / Immunosuppressive Agents / Neoplasms / Neoplasms, Hematologic / Pneumocystis / Steroids1
3Not Yet RecruitingTreatmentTransplantations1
3Not Yet RecruitingTreatmentUrinary Tract Infections (UTIs)1
3Not Yet RecruitingTreatmentSynovitis of osteoarthritis1
3RecruitingNot AvailableOsteoarthrosis3
3RecruitingTreatmentAbdominal Pain (AP)1
3RecruitingTreatmentCardiopulmonary Bypass1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3RecruitingTreatmentCommunity Acquired Respiratory Disease Syndrome1
3RecruitingTreatmentDry Eye Syndrome (DES) / Ophthalmopathy, Thyroid-Associated1
3RecruitingTreatmentImmune Thrombocytopenic Purpura ( ITP )1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3RecruitingTreatmentLymphoma NOS1
3RecruitingTreatmentMembranous Nephropathy1
3RecruitingTreatmentTennis Elbow1
3RecruitingTreatmentThrombocytopenias1
3SuspendedTreatmentSpinal Cord Injuries (SCI)1
3TerminatedTreatmentGlomerulonephritis1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
3WithdrawnTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
3WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentCardiac Surgical Procedures / Cardiopulmonary Bypass / Systemic Inflammatory Response Syndrome (SIRS)1
4Active Not RecruitingTreatmentPlantar fascial fibromatosis2
4Active Not RecruitingTreatmentRelapsing-Remitting Multiple Sclerosis (RRMS)1
4CompletedNot AvailableHealthy Volunteers1
4CompletedPreventionAdrenocortical Deficiency / Hemodynamic Instability1
4CompletedPreventionEsophageal Diseases1
4CompletedPreventionHysterectomy / Methylprednisolone / Postoperative Pain1
4CompletedPreventionLiver Transplant1
4CompletedPreventionTransplantation, Kidney2
4CompletedSupportive CareInflammatory Responses / Lethargy / LOS / Postoperative Pain / Prophylaxis against postoperative nausea and vomiting / Sleeping Quality1
4CompletedSupportive CareInflammatory Responses / Lethargy / Postoperative Pain / Prophylaxis against postoperative nausea and vomiting / Sleeping Quality1
4CompletedTreatmentAcute Asthma / Asthma / Reactive Airway Exacerbation1
4CompletedTreatmentAdrenal Insufficiency / Tendinopathy1
4CompletedTreatmentAlopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia1
4CompletedTreatmentAsthma1
4CompletedTreatmentChildren / Chronic Rhinosinusitis1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentGraft Rejection / Kidney Failure / Transplantation, Kidney1
4CompletedTreatmentHLA Sensitization1
4CompletedTreatmentHeart Transplantation1
4CompletedTreatmentLiver Cirrhosis / Liver Transplant Disorder1
4CompletedTreatmentMigraine Headaches1
4CompletedTreatmentMultiple Sclerosis (MS)1
4CompletedTreatmentRelapsing-Remitting Multiple Sclerosis (RRMS)2
4CompletedTreatmentRheumatoid Arthritis5
4CompletedTreatmentSciatica1
4CompletedTreatmentTransplantation, Kidney1
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentViral Bronchiolitis1
4Enrolling by InvitationTreatmentArthralgia / TMJ1
4Enrolling by InvitationTreatmentCarpal Tunnel Syndrome (CTS)1
4Not Yet RecruitingPreventionGraves Ophthalmopathy1
4Not Yet RecruitingTreatmentOsteoarthritis,Knee1
4RecruitingPreventionDelirium - Postoperative / Stress, Physiological1
4RecruitingTreatmentCalcifying Tendinitis of Shoulder1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
4RecruitingTreatmentFulminant Hepatic Failure1
4RecruitingTreatmentGraves' Ophthalmopathy1
4RecruitingTreatmentMastectomy / Neoplasms, Breast1
4RecruitingTreatmentNephritis, Lupus1
4RecruitingTreatmentTransplantation, Kidney1
4RecruitingTreatmentTransplantation, Renal1
4RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingTreatmentWegener's Granulomatosis, Microscopic Polyangiitis1
4RecruitingTreatmentSynovitis of osteoarthritis1
4TerminatedTreatmentImmune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy1
4TerminatedTreatmentTransplants and Implants1
4WithdrawnTreatmentDemyelinating Disorders / Multiple Sclerosis (MS) / Myelitis / Neuritis / Optic Neuritis1
4WithdrawnTreatmentPediatric Crohn's Disease1
Not AvailableActive Not RecruitingPreventionLeukemias1
Not AvailableActive Not RecruitingTreatmentAnemia, Hemolytic, Autoimmune / Arthritis, Juvenile Rheumatoid / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cell Arteritis / Graft Versus Host Disease (GVHD) / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE) / Takayasu's Arteritis / Vasculitis, Hypersensitivity / Wegener Granulomatosis (WG)1
Not AvailableActive Not RecruitingTreatmentAplastic Anaemia (AA) / Graft Versus Host Disease (GVHD)1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentMultiple Sclerosis (MS) / Optic Neuritis1
Not AvailableCompletedSupportive CarePost-traumatic; Arthrosis / Synovitis of osteoarthritis1
Not AvailableCompletedSupportive CareInflammatory processes / Postoperative Pain1
Not AvailableCompletedTreatmentAbdominal Aortic Aneurysms (AAA)1
Not AvailableCompletedTreatmentBiliary Atresia1
Not AvailableCompletedTreatmentChronic Low Back Pain (CLBP)1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableCompletedTreatmentCongenital Heart Disease (CHD) / Disorder of Fetus or Newborn1
Not AvailableCompletedTreatmentDisc Disease1
Not AvailableCompletedTreatmentEdema / Pain / Trismus1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentHand, Foot, and Mouth Disease1
Not AvailableCompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentTransplantation, Kidney1
Not AvailableEnrolling by InvitationPreventionCervical Degenerative Disc Disease / Cervical Disc Herniation / Cervical Spondylotic Myelopathy / Dysphagia / Osteoarthritis of Cervical Spine1
Not AvailableEnrolling by InvitationSupportive CareSynovitis of osteoarthritis1
Not AvailableEnrolling by InvitationTreatmentOsteoarthritis,Knee1
Not AvailableNot Yet RecruitingPreventionAortic Dissection1
Not AvailableNot Yet RecruitingPreventionHeart Valve Diseases / Systemic Inflammatory Response Syndrome (SIRS)1
Not AvailableNot Yet RecruitingTreatmentChronic Renal Failure (CRF)1
Not AvailableNot Yet RecruitingTreatmentNeuroma, Human Forefoot1
Not AvailableNot Yet RecruitingTreatmentVentral Hernias1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adrenal Insufficiency / Airway Swelling / Anxiety / Anxiolysis / Autistic Disorder / Bacterial Septicemia / Bartonellosis / Benzodiazepine Withdrawal / Bipolar Disorder (BD) / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Edema / Epilepsies / Gastroparesis / Headaches / Herpes Simplex Virus / Hospital Acquired Pneumonia (HAP) / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Hypotension / Infantile Hemangiomas / Infection NOS / Inflammatory processes / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Life-threatening Fungal Infections / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenia / Sedation therapy / Seizures / Sepsis / Skin and Subcutaneous Tissue Bacterial Infections / Stable Angina (SA) / Trachoma / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Vomiting / Withdrawal1
Not AvailableRecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
Not AvailableRecruitingTreatmentAortic Stenosis1
Not AvailableRecruitingTreatmentBiceps Tendonitis / Injections1
Not AvailableRecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableRecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableRecruitingTreatmentCongenital Heart Disease (CHD) / Disorder of Fetus or Newborn1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableRecruitingTreatmentIgA Glomerulonephritis1
Not AvailableRecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
Not AvailableRecruitingTreatmentPneumonia, Pneumocystis1
Not AvailableRecruitingTreatmentPolyp of Nasal Sinus1
Not AvailableRecruitingTreatmentSevere Acute Exacerbation of Chronic Hepatitis B1
Not AvailableRecruitingTreatmentShoulder Pain / Subacromial Bursitis1
Not AvailableRecruitingTreatmentTraumatic Optic Neuropathy1
Not AvailableTerminatedNot AvailableLumbar Back Pain / Lumbar Radiculitis / Lumbar Spine Disc Herniation1
Not AvailableTerminatedTreatmentAcute Graft Versus Host Disease1
Not AvailableTerminatedTreatmentChediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Agammaglobulinemia / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
Not AvailableTerminatedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableTerminatedTreatmentMultiple Sclerosis (MS)1
Not AvailableTerminatedTreatmentRefractory Mycoplasma Pneumoniae Pneumonia1
Not AvailableTerminatedTreatmentShoulder Impingement Syndrome1
Not AvailableWithdrawnDiagnosticLung Cancers1
Not AvailableWithdrawnTreatmentBronchiolitis1
Not AvailableWithdrawnTreatmentDexamethasone / Hiccups1
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Cadista pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Heather drug co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Abbott laboratories hosp products div
  • Hemopharm usa corp
  • Hospira inc
  • Elkins sinn div ah robins co inc
  • Organon usa inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories
  • International medication systems ltd
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/mL
Injection, suspensionIntralesional; Intramuscular; Intrasynovial; Soft tissue20 mg/mL
Injection, suspensionIntralesional; Intramuscular; Intrasynovial; Soft tissue40 mg/mL
Injection, suspensionIntralesional; Intramuscular; Intrasynovial; Soft tissue80 mg/mL
Injection, suspensionIntramuscular40 mg/1
SuspensionIntra-articular; Intralesional; Intramuscular; Intrasynovial20 mg
SuspensionIntra-articular; Intralesional; Intramuscular; Intrasynovial80 mg
SuspensionIntra-articular; Intralesional; Intramuscular; Intrasynovial40 mg
SolutionIntra-articular; Intrabursal
GelTopical10 mg/g
TabletOral2 mg/1
TabletOral32 mg/1
TabletOral16 mg
TabletOral4 mg
CreamTopical2.5 mg
TabletOral16 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue40 mg/mL
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue80 mg/mL
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Soft tissue40 mg/mL
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Soft tissue80 mg/mL
Injection, suspensionIntramuscular; Intrasynovial; Soft tissue40 mg/mL
SuspensionIntra-articular; Intramuscular; Intrasynovial; Soft tissue40 mg
SuspensionIntra-articular; Intramuscular; Intrasynovial; Soft tissue80 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Powder, for solutionIntramuscular; Intravenous1 g
Powder, for solutionIntramuscular; Intravenous125 mg
Powder, for solutionIntramuscular; Intravenous40 mg
Powder, for solutionIntramuscular; Intravenous5 g
Powder, for solutionIntramuscular; Intravenous500 mg
Powder, for solutionIntramuscular; Intravenous
CreamTopical
LotionTopical
Kit
KitEpidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Injection, powder, for solutionIntramuscular; Intravenous1 g/mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous40 mg/1
Kit
Kit; powderIntramuscular; Intravenous1 g
Kit; powderIntramuscular; Intravenous125 mg
Kit; powderIntramuscular; Intravenous40 mg
Kit; powderIntramuscular; Intravenous500 mg
Kit; powder, for solutionIntramuscular; Intravenous1 g
Kit; powder, for solutionIntramuscular; Intravenous125 mg
Kit; powder, for solutionIntramuscular; Intravenous40 mg
Kit; powder, for solutionIntramuscular; Intravenous500 mg
Powder, for solutionIntravenous125 mg/mL
Powder, for solutionIntramuscular; Intravenous; Rectal125 mg
Powder, for solutionIntramuscular; Intravenous; Rectal40 mg
Prices
Unit descriptionCostUnit
Methylprednisolone powder96.25USD g
Methylprednisolone ac powdr40.09USD g
Methylprednisolone ss 1 gm vial31.2USD vial
Solu-medrol 1 gm vial24.43USD vial
Solu-medrol (pf) 500 mg vial20.9USD vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack16.99USD disp
Methylprednisolone 500 mg vial15.6USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Methylprednisolone 125 mg vial10.0USD vial
Methylprednisolone 80 mg/ml vial9.12USD ml
Depo-medrol 40 mg/ml vial6.41USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Methylprednisolone 40 mg/ml vial5.22USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone 32 mg tablet4.62USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone 16 mg tablet3.17USD tablet
Methylprednisolone 40 mg vial3.0USD vial
A-methapred 40 mg vial2.36USD vial
Medrol 16 mg tablet2.28USD tablet
Medrol 8 mg tablet2.23USD tablet
Methylprednisolone 8 mg tablet1.74USD tablet
Methylprednisolone 4 mg tablet1.68USD tablet
Medrol 4 mg dosepak1.59USD each
Medrol 4 mg tablet0.99USD tablet
Medrol 2 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232.5 °CPhysProp
water solubility120 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.5Not Available
logS-2.99ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP2.06ALOGPS
logP1.56ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity103.04 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9484
Caco-2 permeable-0.6404
P-glycoprotein substrateSubstrate0.7812
P-glycoprotein inhibitor INon-inhibitor0.7489
P-glycoprotein inhibitor IINon-inhibitor0.604
Renal organic cation transporterNon-inhibitor0.769
CYP450 2C9 substrateNon-substrate0.8415
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.9473
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9513
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9167
Ames testNon AMES toxic0.9337
CarcinogenicityNon-carcinogens0.9529
BiodegradationNot ready biodegradable0.9492
Rat acute toxicity2.0025 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9459
hERG inhibition (predictor II)Non-inhibitor0.5985
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 21-hydroxysteroid
  • 20-oxosteroid
  • Pregnane-skeleton
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • Oxosteroid
  • 11-beta-hydroxysteroid
  • 11-hydroxysteroid
  • 17-hydroxysteroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Tertiary alcohol
  • Alpha-hydroxy ketone
  • Ketone
  • Secondary alcohol
  • Cyclic ketone
  • Primary alcohol
  • Alcohol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organic oxide
  • Organic oxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172 ]
  2. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711 ]
  3. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119 ]
  4. Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542 ]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46